Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine

30-04-2024 | Positron Emission Tomography | Original Article

Prognostic significance of 68 Ga-FAPI PET/CT in patients with bone metastases in various cancers

Authors: Hacı Arak, Umut Elboga, Yusuf Burak Cayirli, Aydın Aytekin

Published in: Annals of Nuclear Medicine

Login to get access

Abstract

Objective

This study aimed to compare 18FDGPET/CT in patients who develop bone metastases due to various cancers and to investigate the prognostic significance of the 68FAPI-PET/CT SUVmax value for survival.

Methods

Patients with bone metastases who underwent both 68 Ga-FAPI PET/CT and 18FDGPET/CT within a 1 week period were included in this retrospective study. The effect of the SUVmax value of bone lesions on overall survival was analyzed.

Results

A total of 75 eligible patients with 139 bone lesions were included in this study. The median age of the patients was 55 (30–83) and 48(64%) patients were newly diagnosed. The primary lesion median 68 Ga-FAPI PET/CT SUVmax value was higher than the median 18FDGPET/CT SUVmax (10.75 versus 6.7). Bone lesions 68 Ga-FAPI PET/CT SUVmax median (IQR) were 7.8 (4.6–13.2), and 18FDGPET/CT SUVmax of bone lesions were 5.9 (3.8–8.2). More bone lesions were detected on 68 Ga-FAPI PET/CT than on 18FDGPET/CT(median IQR 4 [1–9] versus 2 [1–6] (p = 0.014). The extra lesions observed on 68 Ga-FAPI PET/CT were mostly sclerotic bone lesions (p = 0.001).68 Ga-FAPI PET/CT SUVmax was significantly higher in vertebra and thorax lesions (p = 0.011 and p = 0.018, respectively). While the bone lesion 68 Ga-FAPI PET/CT SUVmax affected the OS, the 18FDGPET/CT SUVmax value did not affect the OS (p < 0.001 and p = 0.079, respectively). In ROC analysis, a cut-off-off value of 68 Ga-FAPI PET/CT SUVmax > 7.7 was found for OS (AUC: 0.619). The median OS in the group above the cut-off value was worse than that in the group below the cut-off value (32 versus 45) months (p = 0.002). In the multivariate analysis for OS, the 68 Ga-FAPI PET/CT SUVmax of bone lesions was an important parameter, as well as cancer subtype, ALP level, and disease occurrence.

Conclusions

68 Ga-FAPI PET/CT detected more bone lesions and higher SUVmax values than 18FDGPET/CT in various cancers. The prognostic value of the SUVmax value of 68 Ga-FAPI PET/CT bone lesions was observed regardless of disease subtype.
Literature
1.
2.
3.
4.
Dong Y, Zhou H, Alhaskawi A, et al. The Superiority of Fibroblast Activation Protein Inhibitor (FAPI) PET/CT Versus FDG PET/CT in the Diagnosis of Various Malignancies. Cancers (Basel). 2023;15(4):1193.CrossRefPubMedPubMedCentral
5.
Guglielmo P, Alongi P, Baratto L, et al. Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature. Life (Basel). 2023;13(9):1821.PubMedPubMedCentral
6.
Eshet Y, Tau N, Apter S, et al. The Role of 68 Ga-FAPI PET/CT in Detection of Metastatic Lobular Breast Cancer. Clin Nucl Med. 2023;48:228–32.CrossRefPubMed
7.
Kömek H, Can C, Kaplan İ, et al. Comparison of [(68) Ga]Ga-DOTA-FAPI-04 PET/CT and [(18)F]FDG PET/CT in colorectal cancer. Eur J Nucl Med Mol Imaging. 2022;49:3898–909.CrossRefPubMed
8.
Chen H, Pang Y, Li J, et al. Comparison of [(68)Ga]Ga-FAPI and [(18)F]FDG uptake in patients with gastric signet-ring-cell carcinoma: a multicenter retrospective study. Eur Radiol. 2023;33:1329–41.CrossRefPubMed
9.
Wu J, Wang Y, Liao T, et al. Comparison of the Relative Diagnostic Performance of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG PET/CT for the Detection of Bone Metastasis in Patients With Different Cancers. Front Oncol. 2021;11: 737827.CrossRefPubMedPubMedCentral
10.
Li L, Hu X, Ma J, Yang S, Gong W, Zhang C. A systematic review of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG PET/CT in the diagnostic value of malignant tumor bone metastasis. Front Oncol. 2022;12: 978506.CrossRefPubMedPubMedCentral
11.
Şahin E, Elboğa U, Çelen YZ, Sever ÖN, Çayırlı YB, Çimen U. Comparison of (68)Ga-DOTA-FAPI and (18)FDG PET/CT imaging modalities in the detection of liver metastases in patients with gastrointestinal system cancer. Eur J Radiol. 2021;142: 109867.CrossRefPubMed
12.
13.
Dondi F, Albano D, Treglia G, Bertagna F. Emerging Role of FAPI PET Imaging for the assessment of benign bone and joint diseases. J Clin Med. 2022;11(15):4514.CrossRefPubMedPubMedCentral
14.
Miao P, Sheng S, Sun X, Liu J, Huang G. Lactate dehydrogenase A in cancer: a promising target for diagnosis and therapy. IUBMB Life. 2013;65:904–10.CrossRefPubMed
15.
Jiang C, Hu F, Li J, Gao G, Guo X. Diagnostic value of alkaline phosphatase and bone-specific alkaline phosphatase for metastases in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2023;202:233–44.CrossRefPubMed
16.
Surov A, Meyer HJ, Wienke A. Associations Between PET Parameters and Expression of Ki-67 in Breast Cancer. Transl Oncol. 2019;12:375–80.CrossRefPubMed
17.
Vaupel P, Multhoff G. Revisiting the Warburg effect: historical dogma versus current understanding. J Physiol. 2021;599:1745–57.CrossRefPubMed
18.
Kreppel B, Gonzalez-Carmona MA, Feldmann G, et al. Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours. Nuklearmedizin. 2021;60:344–54.CrossRefPubMed
19.
Giesen N, Sprute R, Rüthrich M, et al. Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Eur J Cancer. 2020;140:86–104.CrossRefPubMedPubMedCentral
20.
Ji F, Fu SJ, Guo ZY, et al. Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinoma. Medicine (Baltimore). 2016;95: e4065.CrossRefPubMed
21.
Qu X, Huang X, Yan W, Wu L, Dai K. A meta-analysis of 18FDG-PET-CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol. 2012;81:1007–15.CrossRefPubMed
22.
Gross-Erne M, Zimmerli L, Bassetti S, Li Q, Feller A, Mingrone W. A long-term retrospective observational study at a medium-sized medical oncology service in Switzerland: comparison of overall survival with a national cohort and adherence to treatment guidelines. Swiss Med Wkly. 2023;153:40091.CrossRefPubMed
23.
Moore S, Leung B, Wu J, Ho C. Survival Implications of De Novo Versus Recurrent Metastatic Non-Small Cell Lung Cancer. Am J Clin Oncol. 2019;42:292–7.CrossRefPubMed
24.
Miotke L, Nevala-Plagemann C, Ying J, Florou V, Haaland B, Garrido-Laguna I. Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. BMC Cancer. 2022;22:1054.CrossRefPubMedPubMedCentral
25.
Pak K, Cheon GJ, Nam HY, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis. J Nucl Med. 2014;55:884–90.CrossRefPubMed
26.
Marinelli B, Espinet-Col C, Ulaner GA, et al. Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. Am J Nucl Med Mol Imaging. 2016;6:120–7.PubMedPubMedCentral
Metadata
Title
Prognostic significance of 68 Ga-FAPI PET/CT in patients with bone metastases in various cancers
Authors
Hacı Arak
Umut Elboga
Yusuf Burak Cayirli
Aydın Aytekin
Publication date
30-04-2024
Publisher
Springer Nature Singapore
Published in
Annals of Nuclear Medicine
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-024-01935-3